Cell-Free Circulating Tumor DNA (ctDNA) Market, Global Outlook and Forecast 2023-2029
Report ID
36561
Publisher
Market Monitor Global
Published Date
17-Oct
Delivery Format
PDF
No of Report Page
102
Editor's Rating
US $3,250.00
US $4,225.00
US $4,875.00
  • Report Details 
    This research report provides a comprehensive analysis of the Cell-Free Circulating Tumor DNA (ctDNA) market, focusing on the current trends, market dynamics, and future prospects. The report explores the global Cell-Free Circulating Tumor DNA (ctDNA) market, including major regions such as North America, Europe, Asia-Pacific, and emerging markets. It also examines key factors driving the growth of Cell-Free Circulating Tumor DNA (ctDNA), challenges faced by the industry, and potential opportunities for market players.
The global Cell-Free Circulating Tumor DNA (ctDNA) market has witnessed rapid growth in recent years, driven by increasing environmental concerns, government incentives, and advancements in technology. The Cell-Free Circulating Tumor DNA (ctDNA) market presents opportunities for various stakeholders, including Hospital, Medical Center. Collaboration between the private sector and governments can accelerate the development of supportive policies, research and development efforts, and investment in Cell-Free Circulating Tumor DNA (ctDNA) market. Additionally, the growing consumer demand present avenues for market expansion.
The global Cell-Free Circulating Tumor DNA (ctDNA) market was valued at US$ million in 2022 and is projected to reach US$ million by 2029, at a CAGR of % during the forecast period. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.
Key Features:
The research report on the Cell-Free Circulating Tumor DNA (ctDNA) market includes several key features to provide comprehensive insights and facilitate decision-making for stakeholders.
Executive Summary: The report provides overview of the key findings, market trends, and major insights of the Cell-Free Circulating Tumor DNA (ctDNA) market.
Market Overview: The report provides a comprehensive overview of the Cell-Free Circulating Tumor DNA (ctDNA) market, including its definition, historical development, and current market size. It covers market segmentation by Type (e.g., Gastric Cancer Methylation Screening, Esophageal Cancer Methylation Screening), region, and application, highlighting the key drivers, challenges, and opportunities within each segment.
Market Dynamics: The report analyses the market dynamics driving the growth and development of the Cell-Free Circulating Tumor DNA (ctDNA) market. The report includes an assessment of government policies and regulations, technological advancements, consumer trends and preferences, infrastructure development, and industry collaborations. This analysis helps stakeholders understand the factors influencing the Cell-Free Circulating Tumor DNA (ctDNA) market's trajectory.
Competitive Landscape: The report provides an in-depth analysis of the competitive landscape within the Cell-Free Circulating Tumor DNA (ctDNA) market. It includes profiles of major market players, their market share, strategies, product portfolios, and recent developments. 
Market Segmentation and Forecast: The report segment the Cell-Free Circulating Tumor DNA (ctDNA) market based on various parameters, such as by Type, region, and by Application. It provides market size and growth forecasts for each segment, supported by quantitative data and analysis. This helps stakeholders identify growth opportunities and make informed investment decisions.
Technological Trends: The report should highlight the key technological trends shaping the Cell-Free Circulating Tumor DNA (ctDNA) market, such as advancements in Type One technology and emerging substitutes. It analyses the impact of these trends on market growth, adoption rates, and consumer preferences.
Market Challenges and Opportunities: The report identify and analyses the major challenges faced by the Cell-Free Circulating Tumor DNA (ctDNA) market, such as technical bottleneck, cost limitations, and high entry barrier. It also highlights the opportunities for market growth, such as government incentives, emerging markets, and collaborations between stakeholders.
Regulatory and Policy Analysis: The report should assess the regulatory and policy landscape for Cell-Free Circulating Tumor DNA (ctDNA), including government incentives, emission standards, and infrastructure development plans. It should analyse the impact of these policies on market growth and provide insights into future regulatory developments.
Recommendations and Conclusion: The report conclude with actionable recommendations for stakeholders, such as Application One Consumer, policymakers, investors, and infrastructure providers. These recommendations should be based on the research findings and address key challenges and opportunities within the Cell-Free Circulating Tumor DNA (ctDNA) market.
Supporting Data and Appendices: The report include supporting data, charts, and graphs to substantiate the analysis and findings. It also includes appendices with additional detailed information, such as data sources, survey questionnaires, and detailed market forecasts.
Market Segmentation
Cell-Free Circulating Tumor DNA (ctDNA) market is split by Type and by Application. For the period 2018-2029, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of value.
Market segment by Type
    Gastric Cancer Methylation Screening
    Esophageal Cancer Methylation Screening
    Colorectal Cancer Methylation Screening
    Lung Cancer Methylation Screening
    Liver Cancer Methylation Screening
    Other Cancer Screening
Market segment by Application
    Hospital
    Medical Center
    Laboratory
Global Cell-Free Circulating Tumor DNA (ctDNA) Market Segment Percentages, By Region and Country, 2022 (%)
    North America
        US
        Canada
        Mexico
    Europe
        Germany
        France
        U.K.
        Italy
        Russia
        Nordic Countries
        Benelux
        Rest of Europe
    Asia
        China
        Japan
        South Korea
        Southeast Asia
        India
        Rest of Asia
    South America
        Brazil
        Argentina
        Rest of South America
    Middle East & Africa
        Turkey
        Israel
        Saudi Arabia
        UAE
        Rest of Middle East & Africa
Major players covered
    Nexomics
    Roche
    ORIOMICS
    Signatera
    Illumina
    Sysmex Corporation
    Bio-Rad
    Biocartis
    QIAGEN
    GuardantHealth
    GSK plc
    AstraZeneca
    NeoGenomics Laboratories
    AmoyDx
    Annoroad
    Burning Rock Biotech
Outline of Major Chapters:
Chapter 1: Introduces the definition of Cell-Free Circulating Tumor DNA (ctDNA), market overview.
Chapter 2: Global Cell-Free Circulating Tumor DNA (ctDNA) market size in revenue.
Chapter 3: Detailed analysis of Cell-Free Circulating Tumor DNA (ctDNA) company competitive landscape, revenue and market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales of Cell-Free Circulating Tumor DNA (ctDNA) in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space of each country in the world.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 8: The main points and conclusions of the report.
  • Table Of Content 
    1 Introduction to Research & Analysis Reports
    1.1 Cell-Free Circulating Tumor DNA (ctDNA) Market Definition
    1.2 Market Segments
        1.2.1 Market by Type
        1.2.2 Market by Application
    1.3 Global Cell-Free Circulating Tumor DNA (ctDNA) Market Overview
    1.4 Features & Benefits of This Report
    1.5 Methodology & Sources of Information
        1.5.1 Research Methodology
        1.5.2 Research Process
        1.5.3 Base Year
        1.5.4 Report Assumptions & Caveats
2 Global Cell-Free Circulating Tumor DNA (ctDNA) Overall Market Size
    2.1 Global Cell-Free Circulating Tumor DNA (ctDNA) Market Size: 2022 VS 2029
    2.2 Global Cell-Free Circulating Tumor DNA (ctDNA) Market Size, Prospects & Forecasts: 2018-2029
    2.3 Key Market Trends, Opportunity, Drivers and Restraints
        2.3.1 Market Opportunities & Trends
        2.3.2 Market Drivers
        2.3.3 Market Restraints
3 Company Landscape
    3.1 Top Cell-Free Circulating Tumor DNA (ctDNA) Players in Global Market
    3.2 Top Global Cell-Free Circulating Tumor DNA (ctDNA) Companies Ranked by Revenue
    3.3 Global Cell-Free Circulating Tumor DNA (ctDNA) Revenue by Companies
    3.4 Top 3 and Top 5 Cell-Free Circulating Tumor DNA (ctDNA) Companies in Global Market, by Revenue in 2022
    3.5 Global Companies Cell-Free Circulating Tumor DNA (ctDNA) Product Type
    3.6 Tier 1, Tier 2 and Tier 3 Cell-Free Circulating Tumor DNA (ctDNA) Players in Global Market
        3.6.1 List of Global Tier 1 Cell-Free Circulating Tumor DNA (ctDNA) Companies
        3.6.2 List of Global Tier 2 and Tier 3 Cell-Free Circulating Tumor DNA (ctDNA) Companies
4 Market Sights by Product
    4.1 Overview
        4.1.1 By Type - Global Cell-Free Circulating Tumor DNA (ctDNA) Market Size Markets, 2022 & 2029
        4.1.2 Gastric Cancer Methylation Screening
        4.1.3 Esophageal Cancer Methylation Screening
        4.1.4 Colorectal Cancer Methylation Screening
        4.1.5 Lung Cancer Methylation Screening
        4.1.6 Liver Cancer Methylation Screening
        4.1.7 Other Cancer Screening
    4.2 By Type - Global Cell-Free Circulating Tumor DNA (ctDNA) Revenue & Forecasts
        4.2.1 By Type - Global Cell-Free Circulating Tumor DNA (ctDNA) Revenue, 2018-2023
        4.2.2 By Type - Global Cell-Free Circulating Tumor DNA (ctDNA) Revenue, 2024-2029
        4.2.3 By Type - Global Cell-Free Circulating Tumor DNA (ctDNA) Revenue Market Share, 2018-2029
5 Sights by Application
    5.1 Overview
        5.1.1 By Application - Global Cell-Free Circulating Tumor DNA (ctDNA) Market Size, 2022 & 2029
        5.1.2 Hospital
        5.1.3 Medical Center
        5.1.4 Laboratory
    5.2 By Application - Global Cell-Free Circulating Tumor DNA (ctDNA) Revenue & Forecasts
        5.2.1 By Application - Global Cell-Free Circulating Tumor DNA (ctDNA) Revenue, 2018-2023
        5.2.2 By Application - Global Cell-Free Circulating Tumor DNA (ctDNA) Revenue, 2024-2029
        5.2.3 By Application - Global Cell-Free Circulating Tumor DNA (ctDNA) Revenue Market Share, 2018-2029
6 Sights by Region
    6.1 By Region - Global Cell-Free Circulating Tumor DNA (ctDNA) Market Size, 2022 & 2029
    6.2 By Region - Global Cell-Free Circulating Tumor DNA (ctDNA) Revenue & Forecasts
        6.2.1 By Region - Global Cell-Free Circulating Tumor DNA (ctDNA) Revenue, 2018-2023
        6.2.2 By Region - Global Cell-Free Circulating Tumor DNA (ctDNA) Revenue, 2024-2029
        6.2.3 By Region - Global Cell-Free Circulating Tumor DNA (ctDNA) Revenue Market Share, 2018-2029
    6.3 North America
        6.3.1 By Country - North America Cell-Free Circulating Tumor DNA (ctDNA) Revenue, 2018-2029
        6.3.2 US Cell-Free Circulating Tumor DNA (ctDNA) Market Size, 2018-2029
        6.3.3 Canada Cell-Free Circulating Tumor DNA (ctDNA) Market Size, 2018-2029
        6.3.4 Mexico Cell-Free Circulating Tumor DNA (ctDNA) Market Size, 2018-2029
    6.4 Europe
        6.4.1 By Country - Europe Cell-Free Circulating Tumor DNA (ctDNA) Revenue, 2018-2029
        6.4.2 Germany Cell-Free Circulating Tumor DNA (ctDNA) Market Size, 2018-2029
        6.4.3 France Cell-Free Circulating Tumor DNA (ctDNA) Market Size, 2018-2029
        6.4.4 U.K. Cell-Free Circulating Tumor DNA (ctDNA) Market Size, 2018-2029
        6.4.5 Italy Cell-Free Circulating Tumor DNA (ctDNA) Market Size, 2018-2029
        6.4.6 Russia Cell-Free Circulating Tumor DNA (ctDNA) Market Size, 2018-2029
        6.4.7 Nordic Countries Cell-Free Circulating Tumor DNA (ctDNA) Market Size, 2018-2029
        6.4.8 Benelux Cell-Free Circulating Tumor DNA (ctDNA) Market Size, 2018-2029
    6.5 Asia
        6.5.1 By Region - Asia Cell-Free Circulating Tumor DNA (ctDNA) Revenue, 2018-2029
        6.5.2 China Cell-Free Circulating Tumor DNA (ctDNA) Market Size, 2018-2029
        6.5.3 Japan Cell-Free Circulating Tumor DNA (ctDNA) Market Size, 2018-2029
        6.5.4 South Korea Cell-Free Circulating Tumor DNA (ctDNA) Market Size, 2018-2029
        6.5.5 Southeast Asia Cell-Free Circulating Tumor DNA (ctDNA) Market Size, 2018-2029
        6.5.6 India Cell-Free Circulating Tumor DNA (ctDNA) Market Size, 2018-2029
    6.6 South America
        6.6.1 By Country - South America Cell-Free Circulating Tumor DNA (ctDNA) Revenue, 2018-2029
        6.6.2 Brazil Cell-Free Circulating Tumor DNA (ctDNA) Market Size, 2018-2029
        6.6.3 Argentina Cell-Free Circulating Tumor DNA (ctDNA) Market Size, 2018-2029
    6.7 Middle East & Africa
        6.7.1 By Country - Middle East & Africa Cell-Free Circulating Tumor DNA (ctDNA) Revenue, 2018-2029
        6.7.2 Turkey Cell-Free Circulating Tumor DNA (ctDNA) Market Size, 2018-2029
        6.7.3 Israel Cell-Free Circulating Tumor DNA (ctDNA) Market Size, 2018-2029
        6.7.4 Saudi Arabia Cell-Free Circulating Tumor DNA (ctDNA) Market Size, 2018-2029
        6.7.5 UAE Cell-Free Circulating Tumor DNA (ctDNA) Market Size, 2018-2029
7 Cell-Free Circulating Tumor DNA (ctDNA) Companies Profiles
    7.1 Nexomics
        7.1.1 Nexomics Company Summary
        7.1.2 Nexomics Business Overview
        7.1.3 Nexomics Cell-Free Circulating Tumor DNA (ctDNA) Major Product Offerings
        7.1.4 Nexomics Cell-Free Circulating Tumor DNA (ctDNA) Revenue in Global Market (2018-2023)
        7.1.5 Nexomics Key News & Latest Developments
    7.2 Roche
        7.2.1 Roche Company Summary
        7.2.2 Roche Business Overview
        7.2.3 Roche Cell-Free Circulating Tumor DNA (ctDNA) Major Product Offerings
        7.2.4 Roche Cell-Free Circulating Tumor DNA (ctDNA) Revenue in Global Market (2018-2023)
        7.2.5 Roche Key News & Latest Developments
    7.3 ORIOMICS
        7.3.1 ORIOMICS Company Summary
        7.3.2 ORIOMICS Business Overview
        7.3.3 ORIOMICS Cell-Free Circulating Tumor DNA (ctDNA) Major Product Offerings
        7.3.4 ORIOMICS Cell-Free Circulating Tumor DNA (ctDNA) Revenue in Global Market (2018-2023)
        7.3.5 ORIOMICS Key News & Latest Developments
    7.4 Signatera
        7.4.1 Signatera Company Summary
        7.4.2 Signatera Business Overview
        7.4.3 Signatera Cell-Free Circulating Tumor DNA (ctDNA) Major Product Offerings
        7.4.4 Signatera Cell-Free Circulating Tumor DNA (ctDNA) Revenue in Global Market (2018-2023)
        7.4.5 Signatera Key News & Latest Developments
    7.5 Illumina
        7.5.1 Illumina Company Summary
        7.5.2 Illumina Business Overview
        7.5.3 Illumina Cell-Free Circulating Tumor DNA (ctDNA) Major Product Offerings
        7.5.4 Illumina Cell-Free Circulating Tumor DNA (ctDNA) Revenue in Global Market (2018-2023)
        7.5.5 Illumina Key News & Latest Developments
    7.6 Sysmex Corporation
        7.6.1 Sysmex Corporation Company Summary
        7.6.2 Sysmex Corporation Business Overview
        7.6.3 Sysmex Corporation Cell-Free Circulating Tumor DNA (ctDNA) Major Product Offerings
        7.6.4 Sysmex Corporation Cell-Free Circulating Tumor DNA (ctDNA) Revenue in Global Market (2018-2023)
        7.6.5 Sysmex Corporation Key News & Latest Developments
    7.7 Bio-Rad
        7.7.1 Bio-Rad Company Summary
        7.7.2 Bio-Rad Business Overview
        7.7.3 Bio-Rad Cell-Free Circulating Tumor DNA (ctDNA) Major Product Offerings
        7.7.4 Bio-Rad Cell-Free Circulating Tumor DNA (ctDNA) Revenue in Global Market (2018-2023)
        7.7.5 Bio-Rad Key News & Latest Developments
    7.8 Biocartis
        7.8.1 Biocartis Company Summary
        7.8.2 Biocartis Business Overview
        7.8.3 Biocartis Cell-Free Circulating Tumor DNA (ctDNA) Major Product Offerings
        7.8.4 Biocartis Cell-Free Circulating Tumor DNA (ctDNA) Revenue in Global Market (2018-2023)
        7.8.5 Biocartis Key News & Latest Developments
    7.9 QIAGEN
        7.9.1 QIAGEN Company Summary
        7.9.2 QIAGEN Business Overview
        7.9.3 QIAGEN Cell-Free Circulating Tumor DNA (ctDNA) Major Product Offerings
        7.9.4 QIAGEN Cell-Free Circulating Tumor DNA (ctDNA) Revenue in Global Market (2018-2023)
        7.9.5 QIAGEN Key News & Latest Developments
    7.10 GuardantHealth
        7.10.1 GuardantHealth Company Summary
        7.10.2 GuardantHealth Business Overview
        7.10.3 GuardantHealth Cell-Free Circulating Tumor DNA (ctDNA) Major Product Offerings
        7.10.4 GuardantHealth Cell-Free Circulating Tumor DNA (ctDNA) Revenue in Global Market (2018-2023)
        7.10.5 GuardantHealth Key News & Latest Developments
    7.11 GSK plc
        7.11.1 GSK plc Company Summary
        7.11.2 GSK plc Business Overview
        7.11.3 GSK plc Cell-Free Circulating Tumor DNA (ctDNA) Major Product Offerings
        7.11.4 GSK plc Cell-Free Circulating Tumor DNA (ctDNA) Revenue in Global Market (2018-2023)
        7.11.5 GSK plc Key News & Latest Developments
    7.12 AstraZeneca
        7.12.1 AstraZeneca Company Summary
        7.12.2 AstraZeneca Business Overview
        7.12.3 AstraZeneca Cell-Free Circulating Tumor DNA (ctDNA) Major Product Offerings
        7.12.4 AstraZeneca Cell-Free Circulating Tumor DNA (ctDNA) Revenue in Global Market (2018-2023)
        7.12.5 AstraZeneca Key News & Latest Developments
    7.13 NeoGenomics Laboratories
        7.13.1 NeoGenomics Laboratories Company Summary
        7.13.2 NeoGenomics Laboratories Business Overview
        7.13.3 NeoGenomics Laboratories Cell-Free Circulating Tumor DNA (ctDNA) Major Product Offerings
        7.13.4 NeoGenomics Laboratories Cell-Free Circulating Tumor DNA (ctDNA) Revenue in Global Market (2018-2023)
        7.13.5 NeoGenomics Laboratories Key News & Latest Developments
    7.14 AmoyDx
        7.14.1 AmoyDx Company Summary
        7.14.2 AmoyDx Business Overview
        7.14.3 AmoyDx Cell-Free Circulating Tumor DNA (ctDNA) Major Product Offerings
        7.14.4 AmoyDx Cell-Free Circulating Tumor DNA (ctDNA) Revenue in Global Market (2018-2023)
        7.14.5 AmoyDx Key News & Latest Developments
    7.15 Annoroad
        7.15.1 Annoroad Company Summary
        7.15.2 Annoroad Business Overview
        7.15.3 Annoroad Cell-Free Circulating Tumor DNA (ctDNA) Major Product Offerings
        7.15.4 Annoroad Cell-Free Circulating Tumor DNA (ctDNA) Revenue in Global Market (2018-2023)
        7.15.5 Annoroad Key News & Latest Developments
    7.16 Burning Rock Biotech
        7.16.1 Burning Rock Biotech Company Summary
        7.16.2 Burning Rock Biotech Business Overview
        7.16.3 Burning Rock Biotech Cell-Free Circulating Tumor DNA (ctDNA) Major Product Offerings
        7.16.4 Burning Rock Biotech Cell-Free Circulating Tumor DNA (ctDNA) Revenue in Global Market (2018-2023)
        7.16.5 Burning Rock Biotech Key News & Latest Developments
8 Conclusion
9 Appendix
    9.1 Note
    9.2 Examples of Clients
    9.3 Disclaimer
  • Inquiry Before Buying

    Inquiry Before Buying

    Your personal details will remain secure and confidential - Privacy Policy

    WHY CHOOSE US

    Easy Access and Express Report Delivery Service
    Discover Business Growth Opportunities
    More than 10 Years Experience Employee Support
    In-depth and Comprehensive Analysis
    100+ Client Queries Handled Everyday
  • Request Sample

    Request For Sample

    Your personal details will remain secure and confidential - Privacy Policy

    WHY CHOOSE US

    Easy Access and Express Report Delivery Service
    Discover Business Growth Opportunities
    More than 10 Years Experience Employee Support
    In-depth and Comprehensive Analysis
    100+ Client Queries Handled Everyday


Our Trusted Clients
cooper.fr
koronos
waldenmedical
unioncomm.co.kr
technopathclinicaldiagnostics
toho-titanium.co.jp
straubmedical
sew-eurodrive.de
medurifarms
naperol
nvent
network.ae
petronas
saeedghodran
polyworldsys
seedplanning.co.jp
kraton
ipms.fraunhofer.de
infanttech
httpswww.castel-freres
hintoninfo
hexcel
freightways.co.nz
excelitas
Acco
aspet
brand
bmc
elevate
europ-assistance


GET IN TOUCH
Phone: +1 (415) 315-9432
Phone: +91 86698 89536
Email: inquiry@wiredrelease.com
SHORT NAVIGATION
connect with us